PMID: 25731629Mar 4, 2015Paper

Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies

Current Alzheimer Research
Heii AraiTamotsu Yoshiyama

Abstract

Multiple lines of evidence indicate that pathological accumulation of amyloid beta (Aβ) peptide in the brain is linked to the pathophysiology of Alzheimer's disease (AD). Removal of Aβ from the brain by binding to anti-Aβ specific antibodies is under active investigation. Vaccination with a full-length Aβ42 peptide (AN1792) successfully elicited anti-Aβ antibodies in human subjects with AD, but was associated with meningoencephalitis. To avoid this safety issue, an aminoterminal Aβ1-7 peptide conjugate, vanutide cridificar (ACC-001), was designed and is currently in clinical development. This report describes two phase 2 multiple ascending-dose studies in Japanese subjects with mild to moderate AD. Safety and immunogenicity evaluation were the primary and secondary objectives, respectively. ACC-001 was administered to three cohorts of subjects at doses of 3, 10, or 30 μg, with or without a QS-21 adjuvant in Study 1, and with a QS-21 adjuvant in Study 2; control groups consisted of QS-21 alone (both studies) and phosphate-buffered saline (Study 1 only). A variety of treatment-emergent adverse events (TEAEs) were reported from most subjects during the studies; most of these were mild or moderate in intensity. Three subjects withd...Continue Reading

Citations

Oct 24, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Elvira ValeraEliezer Masliah
Jul 21, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael G AgadjanyanAnahit Ghochikyan
Mar 30, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Genevieve Evin
Jul 2, 2016·Molecular Neurodegeneration·Holger CynisCynthia A Lemere
Jul 1, 2016·Expert Reviews in Molecular Medicine·Laia Montoliu-Gaya, Sandra Villegas
Jul 28, 2016·Journal of the American Medical Directors Association·Rosalie M SternerAimee C Yu Ballard
Sep 1, 2016·Expert Review of Vaccines·Jaime I Arevalo-VillalobosSergio Zarazua
Sep 22, 2017·Neurology·Nicolas N MadiganEduardo E Benarroch
Jun 14, 2016·Expert Review of Neurotherapeutics·William James Deardorff, George T Grossberg
Aug 18, 2017·Therapeutic Advances in Chronic Disease·Gopalkumar RakeshAnthony S Zannas
Nov 14, 2019·Neural Regeneration Research·Fausta CiccocioppoSebastiano Miscia
Jul 20, 2017·Journal of Biomedical Science·Shih-Ya Hung, Wen-Mei Fu
Feb 15, 2018·Journal of Alzheimer's Disease : JAD·Cassia Overk, Eliezer Masliah
Oct 20, 2017·Human Vaccines & Immunotherapeutics·Koorosh ShahpasandXiao Zhen Zhou
May 15, 2019·International Journal of Molecular Sciences·Ning ShenChuanhai Cao
Apr 30, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Somin KwonEliezer Masliah
Sep 15, 2020·Journal of Alzheimer's Disease : JAD·Ge SongChuanhai Cao
Sep 18, 2020·European Journal of Pharmacology·Miguel Vaz, Samuel Silvestre
Jun 5, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ou QiaoWenyuan Gao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Related Papers

Translational Neuroscience
Doris Lambracht-Washington, Roger N Rosenberg
Rinshō shinkeigaku = Clinical neurology
Shin-Ei MatsumotoTakeshi Tabira
© 2022 Meta ULC. All rights reserved